Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ACADEMIA
Inlyta Can Be 1st-Choice in 2nd-Line Therapy: Prof. Uemura of Kinki Univ.
At a press seminar sponsored by Pfizer Japan on July 11, Hirotsugu Uemura, professor at Kinki University School of Medicine, said that Pfizer’s renal cell carcinoma (RCC) treatment Inlyta (axitinib) can be a first-choice drug in second-line therapy, pointing out…
To read the full story
ACADEMIA
- Japan Atherosclerosis Society Proposes 3-Tier Lp(a) Risk Framework
September 16, 2026
- Clinical Value of Lp(a) Unchanged despite Pelacarsen PIII Miss: KOL
September 16, 2026
- Yanagisawa Wins Lasker Award for Unlocking Orexin’s Role in Sleep
September 10, 2026
- Generic Shortage Response Evolves into Wakayama’s 1st Regional Formulary
September 3, 2026
- Japan Cancer Database Initiative Aims to Bolster Trial Environment
August 26, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…